FDA trial shows sustained effect for Ozurdex on diabetic
The dexamethasone intraocular implant OZURDEX® (Allergan)
can bring about significant and visual improvement in patients
with diabetic macular oedema, with generally only transient
increases in IOP but with a high incidence of cataract in
phakic patients, said EURETINA president ,Francesco
Bandello MD, told attendees at an EURETINA free paper
session
He reported the pooled results of two FDA studies conducted
by the MEAD study group involving a total of 1048 patients
with diabetic macular oedema. The patients were randomised
into three groups to receive Ozurdex at a dosage of 0.7 mg or
0.35 mg , or sham treatment, with repeated injections when
indicated at intervals no shorter than six months.
Latest Articles
Addressing Postoperative Visual Complications
Managing aberrations after laser refractive surgery requires a multi-layered approach.
3D Printing Helps Transform Ukrainian Eye Care
The country’s ophthalmologists offer valuable experience in treating ocular trauma and prosthesis design.
Winning Essay Says ‘Collective Desire’ Must Drive DEI Implementation
Emerging Microbial Trends That Could Affect Your Practices
A triptych of challenges paints a concerning picture for ophthalmologists across the globe.
Improving Outcomes with Laser-Assisted Surgery
Femtosecond laser offers a multifunctional tool for improving the safety and efficacy of cataract and refractive lens exchange procedures.
Could the Corneal Transplant Pool Increase?
Modifying or discarding major contraindications for keratoplasty could mean more patients have their sight restored.
Matching Premium IOLs to Visual Lifestyles
From monofocal to full-range solutions, each practice needs comprehensive understanding.
Going Dutch on Acanthamoeba Keratitis
A world-first trial suggests a new medication could beat the disease.
Avoiding Intracorneal Ring Segment Complications
Femtosecond lasers are helping improve refractive results with fewer problems.